Fenoprofen
- Atc Codes:M01AE04
- CAS Codes:53746-45-5#34597-40-5#31879-05-7
- PHARMGKB ID:53746-45-5#34597-40-5#31879-05-7
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Genes that may be involved
- Substrate of
- Inhibits
- Induces
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
France: Nalgesic; Greece: Expron, Nazipons.
North America
Canada: Nalfon; USA: Nalfon.
Drug combinations
Chemistry
Fenoprofen Calcium: C~30~H~26~CaO~6~ 2H~2~O. Mw: 558.63. (1) Benzeneacetic acid, α-methyl-3-phenoxy-, calcium salt dihydrate, (±)-; (2) Calcium (±)-m-phenoxyhydratropate dihydrate. CAS-53746-45-5; CAS-34597-40-5 (anhydrous); CAS-31879-05-7 (fenoprofen)(1974).
Pharmacologic Category
Other Nonsteroidal Anti-inflammatory Agents. (ATC-Code: M01AE04).
Mechanism of action
Fenoprofen, a propionic acid derivative, is a prototypical NSAID. It inhibits cyclooxygenase-1 (COX-1/PTGS1) and COX-2/PTGS2, and exhibits anti-inflammatory, analgesic, and antipyretic activity.
Therapeutic use
Relief of mild to moderate pain in adults. Symptomatic treatment of osteoarthritis and rheumatoid arthritis.
Pregnancy and lactiation implications
Teratogenic effects not observed in animal studies. Avoid use in third trimester due to possible premature closure of ductus arteriosus. Very low levels of fenoprofen found in breast milk.
Unlabeled use
Used in symptomatic treatment of juvenile rheumatoid arthritis. Also used in the treatment of ankylosing spondylitis and acute gouty arthritis.
Contraindications
Hypersensitivity to fenoprofen, aspirin, or other NSAIDs, or any component of the formulation. Perioperative pain in setting of CABG surgery. Significant renal dysfunction.
Warnings and precautions
Anaphylactoid reactions might occur (avoid use in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy). Increased risk of adverse cardiovascular thrombotic events, including MI, stroke, and new onset or worsening of pre-existing hypertension (use caution with fluid retention, heart failure, or hypertension). Increased risk of GI events (use caution with history of GI disease (bleeding or ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, elderly or debilitated patients). Skin reactions (including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis) might occur. Severe bronchospasm may occur (do not administer in aspirin-sensitive asthma, and use caution in other forms of asthma). Serious GI toxicity (e.g. bleeding, ulceration, perforation) can occur. Use contraindicated for treatment of perioperative pain in setting of CABG surgery. Risk of MI and stroke may be increased with use following CABG surgery. Severe hepatic reactions (e.g. fulminant hepatitis, liver failure) have occurred with NSAID use, rarely (use with caution in decreased hepatic function). Elevations of serum ALT or AST reported. Anemia reported rarely. May inhibit platelet aggregation and prolong bleeding time. May mask certain signs of infection. NSAID use may cause renal decompensation (not recommended for use in advanced renal disease). Long-term NSAID use may result in renal papillary necrosis. Use with caution in the elderly (increased risk for adverse effects). Withhold for at least 4-6 half-lives prior to surgical or dental procedures.